Cinacalcet

Quick links to important sections

Cinacalcet

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinacalcet

Property Description
Active ingredient Cinacalcet Hydrochloride
Form Film-coated tablet
Pharmacological class Calcimimetic agent
General purpose Parathyroid hormone (PTH) suppressor
Origin Synthetic compound

Cinacalcet is the International Nonproprietary Name (INN) for the synthetic compound Cinacalcet Hydrochloride, which serves as the active pharmaceutical ingredient. It is classified pharmacologically as a Calcimimetic agent, representing a unique and targeted class of drugs used to manage hormonal imbalances. This medicine is designed as a single-active-ingredient product and is formulated as an oral dosage form, specifically a film-coated tablet.


What Type of Medicine is Cinacalcet?

The general purpose of this medicine is to address issues related to the excessive release of parathyroid hormone (PTH). This is achieved by the drug's action as an allosteric modulator that activates the calcium-sensing receptor (CaSR) found on the parathyroid glands. This mechanism causes the gland to respond as if calcium levels were sufficiently high. By suppressing the activity of the gland, Cinacalcet helps to bring about a corresponding decrease in excessive serum calcium levels. This medicine was the first approved drug in the calcimimetic class to specifically enhance the sensitivity of the parathyroid gland to calcium.


General Purpose and Physical Form

Cinacalcet is supplied as a film-coated tablet for the oral route of administration. This formulation facilitates patient accessibility and allows for convenient, continuous administration, which is necessary for maintaining consistent hormonal regulation. This distinctive feature established the INN Cinacalcet as a benchmark agent in the pharmacological management of PTH-related disorders.

What side effects are possible with Cinacalcet?

Possible Side Effects and Safety Information

Cinacalcet's official safety profile, as documented by regulatory authorities, is characterized by effects categorized by frequency and the organ systems involved. The most common adverse reactions are typically gastrointestinal disorders and those related to changes in the body’s mineral balance.


Frequency-Classified Adverse Reactions

The adverse reactions are grouped into standard frequency categories according to official prescribing information:

  • Very Common (Affecting 1 in 10 or more people): Nausea, Vomiting.
  • Common (Affecting up to 1 in 10 people): Hypocalcaemia (low calcium levels), Diarrhoea, Headache, Dizziness, Paraesthesia, Dyspepsia, Anorexia (loss of appetite), Asthenia (weakness), Rash, Myalgia (muscle pain), and Upper respiratory tract infection.

Less frequently documented events, classified as Uncommon or Rare, include hypersensitivity reactions, gastrointestinal bleeding, and the risk of Convulsions (seizures), which is considered a Serious Adverse Reaction.


Serious Safety Considerations

The primary safety concern documented in regulatory labeling is the risk of severe symptomatic hypocalcaemia, which can manifest with symptoms such as tetany and seizures. Cinacalcet is formally contraindicated in individuals with pre-existing low serum calcium levels. Furthermore, the label advises caution regarding the risk of QT interval prolongation associated with a significant decrease in serum calcium.


Population-Specific Safety Notes

Official documents note specific risks for certain groups. Due to increased drug exposure, patients with moderate to severe hepatic impairment require close monitoring during dose adjustment. Additionally, life-threatening events linked to hypocalcaemia have been reported in the paediatric population.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Cinacalcet is officially documented to result from an excessive suppression of parathyroid hormone, leading to severe or symptomatic hypocalcemia (significantly low blood calcium). The manifestations listed in regulatory documents include paresthesias (numbness or tingling), muscle cramping, tetany, convulsions (seizures), and gastrointestinal effects such as nausea and vomiting. The primary physiological systems affected are the neuromuscular and cardiovascular systems.

Scope Element Official Regulatory Documentation
Severe Outcomes Risk of life-threatening events and fatal outcomes linked to profound hypocalcemia. This severe metabolic state includes the risk of QT prolongation and potential ventricular arrhythmia.
Emergency Actions Seek immediate medical attention is mandated if symptoms of hypocalcemia occur. Emergency services should be contacted immediately for life-threatening events such as seizures.
Supportive Management Management is symptomatic and supportive. There is no specific antidote known. Treatment requires withholding Cinacalcet and administering calcium supplements (oral or intravenous) and Vitamin D sterols. Hemodialysis is ineffective.
Population Notes Fatal outcomes due to severe hypocalcemia have been reported in pediatric patients. Close monitoring is required for patients with moderate to severe hepatic impairment due to increased drug exposure.

The official overdose profile requires urgent intervention to manage the severe metabolic consequence of low calcium levels. This includes mandated close monitoring to mitigate the risk of serious cardiac or neurological complications, as specified in regulatory guidance.

Therapeutic Uses of Cinacalcet

Cinacalcet is a prescription medication utilized to address specific conditions related to the parathyroid glands and elevated levels of calcium in the blood.

Quick Facts

  • Therapeutic Domains: Management of secondary hyperparathyroidism in adults with chronic kidney disease who are receiving dialysis.
  • Calcium Management: Used for the treatment of elevated calcium levels (hypercalcemia) in adult patients with parathyroid carcinoma.
  • Primary HPT: An option for addressing severe hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy (surgical removal of the gland).

The medication's primary applications are centered on supporting the maintenance of mineral balance in the body, which is critical for bone and cardiovascular health. It is designated for addressing secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. This helps in managing the appropriate levels of parathyroid hormone (PTH).

Cinacalcet is also indicated for reducing elevated calcium concentrations in the blood associated with parathyroid carcinoma. Additionally, it is used to manage severe hypercalcemia in individuals with primary hyperparathyroidism for whom surgery is not a suitable option.

Eligibility and Restrictions for Use

Cinacalcet's official eligibility is strictly defined by regulatory bodies, establishing clear rules for who can and cannot receive the medication. Treatment must not be initiated in patients with a known hypersensitivity to Cinacalcet or its excipients. The most critical absolute contraindication is pre-existing hypocalcemia; if the patient's serum calcium level is below the lower limit of the normal range, the drug is prohibited for initiation.

The medicine is primarily intended for adult patients with Chronic Kidney Disease (CKD) on dialysis for Secondary Hyperparathyroidism (HPT), as well as those with Parathyroid Carcinoma or Primary HPT who are unable to undergo parathyroidectomy. Use in patients with CKD who are not on dialysis is not indicated due to unestablished long-term safety and an increased risk of hypocalcemia.

Age restrictions vary by region: while US labeling states that Cinacalcet is not indicated for children, European regulatory bodies permit use for Secondary HPT in children aged three years and older who are on maintenance dialysis. Patients with moderate to severe hepatic impairment require use with caution and close monitoring. During pregnancy, use is restricted to cases where the potential benefit explicitly justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Cinacalcet Interactions with other medicines and products

Cinacalcet has significant interactions with other medicinal products based on two primary mechanisms: its effect on drug-metabolizing enzymes and its influence on serum calcium levels.

Pharmacokinetic Interactions (Enzyme-Based)

Interaction Type Interacting Medicines/Classes Management Note
Cinacalcet as Inhibitor CYP2D6 Substrates (e.g., flecainide, metoprolol, tricyclic antidepressants like desipramine) Cinacalcet is a strong inhibitor of CYP2D6. This can significantly increase the blood levels of co-administered medicines predominantly metabolized by this enzyme, particularly those with a narrow therapeutic index. Dose adjustments for the co-administered drug may be necessary.
Cinacalcet as Substrate Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, erythromycin) Cinacalcet is metabolized by CYP3A4. Strong inhibitors of this enzyme can increase cinacalcet exposure. Close monitoring of parathyroid hormone (iPTH) and serum calcium is required, and a cinacalcet dose adjustment may be necessary.
Cinacalcet as Substrate Strong CYP3A4 Inducers (e.g., rifampin, phenytoin) These medicines can reduce cinacalcet blood levels, potentially leading to a loss of efficacy. Monitoring and cinacalcet dose adjustments may be needed.

Pharmacodynamic Interactions

Co-administration with other medicinal products known to lower serum calcium may increase the risk of severe hypocalcemia. The use of cinacalcet with another calcimimetic, etelcalcetide, is contraindicated due to the high risk of severe hypocalcemia. Patients with impaired hepatic function may also have increased cinacalcet exposure, which requires close monitoring.

Mechanism of Action

How Cinacalcet Works: Mechanism of Action

Cinacalcet is a calcimimetic agent that acts by modulating a key receptor within the endocrine system regulating mineral homeostasis. Its action is strictly focused on pathway modulation in the parathyroid glands.


Calcium-Sensing Receptor (CaSR) Modulation

Cinacalcet's primary mechanism involves binding to the Calcium-Sensing Receptor (CaSR) found on the surface of the parathyroid gland chief cells. . The drug allosterically increases the receptor's sensitivity to extracellular calcium, initiating downstream signaling that is characteristic of high calcium concentrations.


Inhibition of Parathyroid Hormone (PTH) Secretion

This enhanced activation of the CaSR initiates a molecular cascade within the parathyroid cell, signaling the gland to suppress the release and synthesis of Parathyroid Hormone (PTH). This mechanistic action results in the reduction of hormonal signaling within the parathyroid regulatory pathway.


Systemic Mineral Balance Adjustment

The resulting sustained reduction in circulating PTH levels leads to key physiological adjustments. Lower PTH activity decreases the movement of calcium and phosphate from bone into the blood and alters the renal handling of minerals. This effect results in the adjustment of serum calcium and phosphate concentrations.

Dosage and Administration Information

Cinacalcet is administered solely via the oral route using film-coated tablets available in strengths of 30 mg, 60 mg, and 90 mg (expressed as cinacalcet free base equivalent). The entire procedural structure is governed by specific instructions regarding timing and physical administration.

The tablet must be taken with food or shortly after a meal to optimize drug absorption and must be swallowed whole without being chewed, crushed, or divided. If a dose is missed, patients must skip the missed dose and simply resume the normal schedule at the next designated time, without attempting to take two doses.

Indication Starting Dose Maximum Daily Dose Frequency
Secondary HPT (Dialysis) 30 mg 180 mg Once daily
Parathyroid Carcinoma / Primary HPT 30 mg 360 mg (90 mg QID) Twice daily, up to four times daily

The treatment schedule is highly structured, relying on defined starting doses for each approved indication, as summarized above. Dosage adjustments are not continuous; rather, they follow a regulated minimum interval, occurring no more frequently than every 2 to 4 weeks, regardless of the indication. This mandatory spacing dictates the schedule for achieving the final maintenance regimen. For those with moderate to severe hepatic impairment, the starting dose remains unchanged, but the subsequent titration phase requires careful attention due to potential differences in drug exposure. This systematic approach ensures controlled administration for all patient groups.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cinacalcet


Evidence for use in Secondary Hyperparathyroidism (SHPT) in Dialysis Patients

Research where Cinacalcet was studied for secondary hyperparathyroidism in adults undergoing maintenance dialysis has primarily been conducted using Randomized Controlled Trials (RCTs) and systematic reviews. These studies monitored changes in key biochemical markers, including levels of parathyroid hormone (PTH), serum calcium, and serum phosphorus. Studies reported consistent measurements showing changes in the levels of PTH and these serum mineral markers in the observed populations. Studies examined the incidence of parathyroidectomy (surgery) and reported that the measure was observed less often in the groups studied compared to control groups.

Researchers also explored the drug's connection to major long-term clinical events, such as cardiovascular hospitalizations and all-cause mortality. Large, long-term trials reported that the measured incidence of major cardiovascular events and all-cause mortality did not show a significant difference compared to control groups over the study period. Therefore, certainty remains low regarding the effect on all-cause and cardiovascular mortality in patients with SHPT on dialysis.


Evidence for use in Primary Hyperparathyroidism (PHPT)

Evidence for the use of Cinacalcet for managing severe hypercalcemia in adult patients with primary hyperparathyroidism (PHPT) who are unable or unwilling to have surgery comes from Randomized Controlled Trials (RCTs). The research examined changes in serum calcium and PTH levels. Studies reported that a significant proportion of participants experienced measurements reflecting a reduction in elevated serum calcium levels. Research explores whether Cinacalcet was associated with the management of high calcium in this group.

What remains uncertain is the long-term impact on bone structure. Reported outcomes regarding changes in bone mineral density were variable or inconsistent across different skeletal measurement sites. The available evidence primarily provides insight into short-term changes in biochemical markers rather than long-term clinical or skeletal consequences.


Evidence in Special Populations and Research Gaps

Research has explored how long the observed measurements related to Cinacalcet are maintained, with some extension studies observing patient data for up to several years. However, the majority of high-quality evidence from RCTs applies specifically to adults undergoing maintenance dialysis. Long-term outcomes for Cinacalcet in the SHPT patient population who are not yet on dialysis have not been fully established through large, controlled trials, and research is still ongoing in this area.

Key Studies & References

  1. The impact of cinacalcet on the serum phosphorus, calcium and PTH levels in dialysis patients; a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Cinacalcet (FAQ)

Q: Is Cinacalcet a form of hormone replacement?

A: No, Cinacalcet is not a hormone replacement medicine. It is classified as a calcimimetic agent, meaning it works by increasing the sensitivity of the parathyroid gland's calcium-sensing receptor to calcium, which then signals the gland to suppress the excessive release of parathyroid hormone (PTH).


Q: Are there other ways to manage high parathyroid hormone levels besides Cinacalcet?

A: According to official guidelines, Cinacalcet may be used alongside other treatments to help manage mineral levels. Specifically, calcium-containing phosphate binders and/or vitamin D sterols are sometimes used in combination with Cinacalcet to assist in adjusting serum calcium levels.


Q: Is Cinacalcet the same kind of drug as calcium supplements?

A: Cinacalcet is structurally and functionally different from calcium supplements. Cinacalcet is a calcimimetic that works to lower parathyroid hormone and mineral levels in the blood. In contrast, calcium supplements are used to increase the amount of calcium available to the body.


Q: How quickly does Cinacalcet start to affect hormone levels?

A: Studies on the drug’s absorption indicate that the highest concentration of the medicine in the blood is typically reached within two to six hours after taking a dose. For determining effectiveness, official guidelines recommend that serum mineral levels be monitored within one to four weeks after starting the medicine.


Q: Is Cinacalcet safe for people with liver problems?

A: Official information states that patients with moderate to severe hepatic impairment (liver problems) may experience increased drug exposure. For this reason, regulatory information indicates that close monitoring of serum calcium, phosphorus, and parathyroid hormone levels is necessary.


Q: Can Cinacalcet cause heart problems?

A: Significant lowering of serum calcium caused by Cinacalcet can potentially lead to effects on the heart, including QT interval prolongation and ventricular arrhythmia. Furthermore, cases of hypotension (low blood pressure) and worsening heart failure have been reported in official documents.


Q: Is it common to feel tired after starting Cinacalcet?

A: Yes, feeling a lack of energy or being weak is documented as a common occurrence. Asthenia (the medical term for weakness) is listed in official product information as a Common adverse reaction, affecting up to 1 in 10 people.


Q: Can Cinacalcet affect my blood pressure?

A: Official regulatory documents list hypotension (low blood pressure) as a risk associated with Cinacalcet. This effect is often linked to a substantial decrease in serum calcium levels following the start of treatment.


Q: Is it possible for Cinacalcet to interact with common pain relievers?

A: Cinacalcet is classified as a strong inhibitor of the CYP2D6 enzyme, which is responsible for metabolizing many other medications, including some types of pain relievers. If a pain reliever is metabolized by this enzyme, its levels in the blood may increase, and regulatory documents indicate that dose adjustments for co-administered drugs may be a required step in management.


Q: Is there a known interaction between Cinacalcet and blood thinners?

A: Cinacalcet affects several drug-metabolizing enzymes in the body (CYP3A4 and CYP2D6). If a specific blood thinner (anticoagulant) is also metabolized by these enzymes, its blood levels could be affected, and close patient monitoring is typically advised in these instances.


Q: Does Cinacalcet interact with any antibiotics?

A: Yes, Cinacalcet interacts with medications that inhibit the CYP3A4 enzyme. Regulatory sources state that strong inhibitors of this enzyme, such as certain macrolide antibiotics (e.g., erythromycin), can increase the blood levels of Cinacalcet itself.


Q: How does Cinacalcet affect the body's use of vitamin D?

A: Cinacalcet works on the pathway that helps control mineral levels, which is closely linked to Vitamin D. If serum calcium levels fall too low during treatment, official guidelines may recommend initiating or increasing the dose of vitamin D sterols and providing supplemental calcium.


Q: Is Cinacalcet considered a life-long treatment?

A: The official product information does not specify a fixed treatment duration. The treatment duration is individualized and relies on the condition being treated and the results of ongoing lab monitoring.


Q: What is the research evidence for Cinacalcet's effect on parathyroid hormone?

A: Clinical trials have examined the effect of the medicine by measuring intact parathyroid hormone (iPTH) levels. Regulatory summaries indicate that Cinacalcet treatment resulted in a reduction in mean iPTH levels from the starting levels when compared to control groups.


Q: What kind of studies have been done on Cinacalcet in children?

A: Official documents note that life-threatening events related to low calcium have been reported in the pediatric population. Studies have been conducted in children aged 28 days to younger than 6 years with chronic kidney disease receiving dialysis to evaluate the drug's safety, tolerability, and pharmacokinetics.


Q: Can Cinacalcet be used during pregnancy?

A: Official labeling places the medicine in FDA Pregnancy Category C, meaning animal studies have shown adverse effects. Use is therefore restricted to cases based on the potential benefit justifying the potential risk, as assessed using official product information.


Q: What are the official guidelines regarding the use of Cinacalcet while breastfeeding?

A: It is unknown if Cinacalcet is present in human milk, though it was found to be excreted in the milk of lactating rats. The decision on whether to use the medicine while breastfeeding requires careful consideration of the importance of the drug to the mother versus the unknown effects on the nursing infant.


Q: Is it normal to feel no changes after starting Cinacalcet?

A: Yes, it is possible to feel no changes. Cinacalcet primarily works by adjusting hormone and mineral levels in the blood, which are typically monitored and managed through periodic lab tests. The focus of the treatment is on achieving target biochemical marker levels, not necessarily on subjective feelings.


Q: Can Cinacalcet cause a headache?

A: Yes, official product safety information includes Headache as a documented adverse reaction. It is listed as a Common side effect, affecting up to 1 in 10 people.


Q: What should I do if I suspect an interaction between Cinacalcet and another drug?

A: Official guidance indicates that all medicines being taken, including prescription and non-prescription items, must be reported to the prescribing healthcare provider. This ensures that any necessary monitoring or adjustments for drug-drug interactions can be implemented.


Q: How long does the effect of one dose of Cinacalcet typically last?

A: According to pharmacokinetic data, the amount of time it takes for half of the drug to be eliminated from the body (the terminal half-life) is reported to be between 30 and 40 hours following oral administration.


Q: If I am taking another medication for my kidney condition, can I still take Cinacalcet?

A: Yes, Cinacalcet is commonly used alongside other medications for kidney-related conditions. Regulatory documents note that the medicine can be used in combination with agents like vitamin D sterols and/or phosphate binders, which requires careful monitoring as specified in official product information.


Q: Are there any gender-specific considerations for using Cinacalcet?

A: Pharmacokinetic analyses suggest that there are some differences based on gender. Official reviews indicate that female subjects may show a lower apparent clearance (rate of removal from the body) of the drug compared to male subjects, which may be a consideration when monitoring the dose.

How should Cinacalcet be stored and disposed of?

Storage and Disposal Requirements for Cinacalcet

Cinacalcet film-coated tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted up to 30 C. It is mandatory to keep the container tightly closed and protect the medicine from freezing, excess heat, moisture, and direct light.

The medication must be stored safely out of the sight and reach of children. Unused, expired, or no longer needed tablets should not be discarded via household waste or wastewater. Disposal must adhere to local regulations, and instruction on proper handling should be sought from a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cinacalcet found in:

A-Z Index: